Newsletter
OneSource Specialty Pharma has partnered with Germany's Formycon to manufacture biosimilars for global markets.
Biosimilars are lower-cost versions of complex biological medicines used to treat diseases like cancer, arthritis and diabetes.
OneSource is an Indian contract development and manufacturing company (CDMO) that helps global pharmaceutical firms develop and manufacture complex biologic medicines.
Formycon, listed in Germany, is a biosimilar developer with three approved products already in the market and four more in its pipeline.
What’s the deal: under the partnership, Formycon will develop the medicines, while OneSource will manufacture them end-to-end from its Bengaluru biologics facility.
This includes everything from cell line development and drug substance production to the final injectable product ready for commercial use.
Why it matters: manufacturing biosimilars require advanced technology, strict quality standards and significant investment, making it a high-entry-barrier business.
Several biologic drugs are nearing the end of their patent protection. Once those patents expire, other companies can start making biosimilars, opening up a multi-billion-dollar global market.
Zoom out: India has already approved more than 140 biosimilars, one of the highest numbers globally, but the country still accounts for only a small share of the global biologics market, which is worth over $450 billion.
Meanwhile, the global biosimilars market is expected to cross $100 billion by the early 2030s.
